Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a dose-finding study; therefore, there is no hypothesis testing

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Albumin-Bound Paclitaxel; Antibodies, Monoclonal; Carboplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Patients with metastatic solid tumors, for whom carboplatin and paclitaxel are appropriate;

• Patients >18 years of age;

• Good performance status;

• Adequate bone marrow and organ function

Exclusion Criteria:

• Previous treatment with any other compound that targets CD40

• Current or planned concurrent treatment with any anticancer agent;

• Patients who have received bone marrow transplant;

• History of autoimmune disorder

• History (within the previous year) of heart failure or heart attack

• Cancer-associated coagulation disorders